NUVB News | Roxom Stocks

Invest Private Security Newsroom

Market Overview

Indices and commodities.

Bitcoin treasury preferreds.

The artificial intelligence theme.

Bitcoin Treasuries

Companies holding bitcoin.

Sectors, global markets and rates.

Popular Portfolios

13F filings, smart money.

Borrow USDT or USDC against your BTC without giving it up.

Switch your bitcoin-backed loan and pay less interest.

Borrow, invest, keep the spread.

Stock Dividends

Dividends from tokenized equities.

Company

Our leadership team, mission, and investors.

Vision, purpose, and architecture behind Roxom.

Terms, privacy, and disclosures.

Resources

Guides, FAQs & support.

Trading logic, platform rules, and fundamentals.

Connect, authenticate, and build with our API.

Current platform health and incidents.

Loading chart

Pay with

1 BTC

=

- USD

Loading market data...

Loading chart

Pay with

NU

Mkt Cap

$1.56B

Volume

3.85M

Next Earnings

November 2nd

Loading chart

NU

NUVBNuvation Bio Inc.

NUVB

Pay with—

Available Balance0.00

NU

Mkt Cap

$1.67B

Volume

3.85M

Next Earnings

November 2nd

Chart Financials Earnings News About Insider Filings

Nuvation Bio Stock Is Up 190% Despite Recent Pressure. Should Investors Care About This $753,000 Insider Sale?Nuvation Bio's Chief People Officer Stacy Markel sold 125,000 shares worth $753,000 on June 23, 2026, reducing her direct holdings by 79.32%. However, the sale was executed under a pre-established trading plan adopted in December 2025, and Markel retains significant exposure through 629,810 outstanding options. Despite the stock's 190% surge over the past year and recent 40% pullback from December highs, the article suggests investors should focus more on the company's ability to convert regulatory wins into commercial growth, particularly with taletrectinib's global launch.The Motley Fool · Jun 29, 2026

Veteran Pharma VC Insider Buys 25,000 Nuvation Bio Shares as New Drug Gains MomentumRobert Mashal, an oncology-trained director at Nuvation Bio, purchased 25,000 shares at $4.73 per share on June 9, 2026, bringing his total indirect holdings to 225,000 shares. The purchase comes as Nuvation's first FDA-approved cancer drug, Ibtrozi, continues gaining traction with over 200 new patients per quarter since its July 2025 launch. The stock has surged 96% over the past year, and Wall Street projects revenue will nearly triple to $203 million in 2026.The Motley Fool · Jun 17, 2026

Insider Sells 200K Shares of Biotech Company Nuvation Bio (NUVB)Kerry Wentworth, Chief Regulatory Officer of Nuvation Bio, sold 200,000 Class A shares for approximately $904,000 on April 6, 2026, reducing his direct holdings by 79%. However, he retains 53,000 shares and 700,000 stock options, suggesting the sale is a routine profit-taking exercise rather than a loss of confidence in the company. Nuvation Bio, a clinical-stage oncology biotech with promising pipeline candidates, reported a net loss of $204.6 million but this is typical for R&D-heavy biotech firms.The Motley Fool · Apr 13, 2026

NUVB Investors Have Opportunity to Join Nuvation Bio Inc. Fraud Investigation with the Schall Law FirmThe Schall Law Firm is investigating Nuvation Bio Inc. for potential securities law violations following the company's Q4 2025 earnings report. The company revealed that 75% of treatment discontinuations for its IBTROZI oncology therapy occurred in later-line patient populations, contributing to a gap between patient starts and revenue growth. The stock fell 25.3% following this disclosure, prompting the investigation into whether the company issued false or misleading statements.Benzinga · Mar 21, 2026

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in PayPal Holdings, Inc. of Class Action Lawsuit and Upcoming Deadlines – PYPLPomerantz Law Firm has filed class action lawsuits against PayPal Holdings and Snowflake Inc., with deadlines for investors to join. PayPal announced disappointing Q4 2025 earnings, CEO departure, and withdrawn 2027 guidance due to macroeconomic factors and operational issues. The firm is also investigating claims on behalf of Nuvation Bio investors.GlobeNewswire Inc. · Mar 10, 2026

New Treatment Modalities Are Reaching Cancers That Resisted Everything ElseSeveral biotech companies are advancing novel cancer treatments through clinical development. Oncolytics Biotech received FDA Fast Track Designation for pelareorep in KRAS-mutant colorectal cancer, showing doubled survival benefits. Novocure gained FDA approval for Optune Pax for pancreatic cancer. Perspective Therapeutics presented positive interim data for its radiopharmaceutical VMT-α-NET. ImmunityBio launched a Phase 2 trial for its CAR-NK cell therapy combined with IL-15 superagonist. Nuvation Bio expanded its Phase 3 trial for safusidenib in IDH1-mutant glioma.Benzinga · Feb 17, 2026

Nuvation Bio Chief Scientist Sells 100,000 Shares Under Trading Plan — Here's What to Know About the StockGary Hattersley, chief scientific officer at Nuvation Bio, exercised and sold 100,000 shares under a pre-planned trading strategy, reducing his direct stock ownership to zero while retaining 298,935 stock options.The Motley Fool · Nov 3, 2025

Intel, XPeng And Other Big Stocks Moving Lower In Wednesday's Pre-Market SessionU.S. stock futures were lower this morning, with the Nasdaq futures falling by around 0.2% on Wednesday. Shares of Intel Corporation (NASDAQ: INTC) fell sharply in today’s pre-market trading after the company outlined a new financial framework for its foundry business. After the market close on Tuesday, Intel announced a new financial reporting structure designed to drive increased cost discipline and higher returns by providing greater transparency, accountability and incentives across the business. Intel shares dipped 4.8% to $41.85 in pre-market trading. Here are some big stocks recording losses in today’s pre-market trading session. Mesoblast Limited (NASDAQ:Benzinga · Apr 3, 2024

Why LuxUrban Hotels Shares Are Trading Lower By Around 27%? Here Are Other Stocks Moving In Wednesday's Mid-Day SessionShares of LuxUrban Hotels Inc. (NASDAQ: LUXH) fell sharply during Wednesday’s session after the company issued preliminary fourth-quarter revenue outlook below estimates. LuxUrban said it expects preliminary revenue of $28.2 million for the fourth quarter, versus market estimates of $34.199 million, according to data from Benzinga Pro. LuxUrban Hotels shares dipped 27.4% to $1.5523 on Wednesday. Here are some other stocks moving in today's mid-day session. Gainers MariaDB plc (NYSE: MRDB) climbed 70.4% to $0.3850 after Progress Software announced that it is possibly considering an offer for the company. Lixte Biotechnology Holdings, Inc. (NASDAQ: LIXT) shares jumped 68.6% to $3.8099 after the company announced the publication of pre-clinical data on its lead clinical compound, LB-100. Nutriband Inc. (NASDAQ: NTRB) gained 33.2% to $3.9950 after the company provided a clinical and regulatory path overview for its AVERSA Fentanyl patch. Verb Technology Company, Inc. (NASDAQ: VERB) surged 30.5% to $0.3656 after the company announced that its MARKET.live entered into a formal partnership with TikTok to become a service provider for TikTok Shop and will receive a TikTok Shop Partner designation. PaySign, Inc. (NASDAQ: PAYS) gained 28.2% to $4.3299 after the company announced better-than-expected fourth-quarter results. Destiny Tech100 Inc (NASDAQ: DXYZ) rose 26.6% to $11.39 after gaining 9% on Tuesday. PAVmed Inc. (NASDAQ: PAVM) gained 19.7% to $2.4798 after the company issued business update and fourth quarter financial results. Noah Holdings Limited (NYSE: NOAH) rose 17.5% to $11.89 after the company reported fourth quarter financial results. NuScale Power Corporation (NYSE: SMR) rose 17.5% to $4.89. The ONE Group Hospitality, Inc. (NASDAQ: STKS) shares rose 17.2% to $4.70 after the company announced that it will ...Benzinga · Mar 27, 2024

Cintas Reports Upbeat Earnings, Joins PaySign, Noah Holdings And Other Big Stocks Moving Higher On WednesdayU.S. stocks were higher, with the Dow Jones index gaining around 300 points on Wednesday. Shares of Cintas Corporation (NASDAQ: CTAS) rose sharply during Wednesday’s session after the company reported better-than-expected third-quarter financial results and raised FY24 guidance. Cintas posted GAAP earnings of $3.84 per share, beating market estimates of $3.59 per share. The company’s quarterly sales came in at $2.406 billion, versus expectations of $2.386 billion, according to data from Benzinga Pro. Cintas shares climbed 9.7% to $694.62 on Wednesday. Here are some other big stocks recording gains in today’s session. PaySign, Inc. (NASDAQ: PAYS) shares jumped 28.2% to $4.3299 after the company announced better-than-expected fourth-quarter results. Noah Holdings Limited (NYSE: NOAH) climbed 17.5% to $11.89 ...Benzinga · Mar 27, 2024

to start trading

NU

NUVBNuvation Bio Inc.

NUVB

Pay with—

Available Balance0.00

Your PositionYou don't own any NUVB yet.

Related Tickers

Earnings